Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + Fruquintinib + Radiotherapy vs Fruquintinib in mCRC
NCT07502014Phase 2Not yet recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in colorectal cancer (CRC), sponsored by Huazhong University of Science and Technology. Planned start May 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07502014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502014.